Table 1.

Patient characteristics. Serum levels of lactate dehydrogenase and S100 are given for the initiation of the first BRAFi+MEKi combination.

	Stage IV n = 87	Adjuvant Stage III n = 7
Gender
Male	43 (49%)	5 (71%)
Female	44 (51%)	2 (29%)
Age	Median 55 years (range 19–85)	Median 62 years (range 43–83)
Previous systemic treatment lines
None	37 (43%)	6 (86%)
PD1 + CTLA4-inhibitors	19 (22%)
PD1-inhibitor monotherapy	18 (21%)	1 (14%)
Interferon α	8 (9%)
BRAF inhibitor monotherapy	4 (5%)
Dacarbazine	1 (1%)
Serum lactate dehydrogenase
Normal	34/72 (47%)	5 (71%)
Elevated	38/72 (53%)	2 (29%)
S100 serum levels
Normal	27/68 (40%)	5 (71%)
Elevated < 2 × ULN	16/68 (24%)
Elevated ≥ 2 ×ULN	25/68 (37%)	2 (29%)